IGNYTE was a single-arm open-label trial testing the efficacy of adding of vusolimogene oderparepvec (RP1), a next-generation HSV-1-modified virus containing deletions of two copies of RL1 encoding ICP34.5, deletion of US12 encoding ICP47, engineered up-regulation of US11 via placing under control of a strong constitutively active promoter, transgenic expression of human GM-CSF, and transgenic expression of Gibbon ape leukemia virus fusogenic glycoprotein (GALV-GP R-), to nivolumab in patients with anti-PD-1-failed melanoma [40]. Here, CSF2 is linked to melanoma.